Revised SPCs: Diflucan (fluconazole) products
SPC updated to note exposure to tolvaptan (CYP3A4 substrate) is significantly increased when co-administered with fluconazole (moderate CYP3A4 inhibitor), with risk of significant increase in adverse reactions; tolvaptan dose should be used when they are used concomitantly.
Source:
electronic Medicines compendium